Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

Early research suggests the immune system may one day be trained to prevent cancer in people with inherited risk.

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

He's lost his father, a brother, aunts, uncles and extended family members to cancer — many of them in their 30s and 40s.

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The preventive immunization Nous-209 works in an initial trial with patients who have 17 times the risk of developing tumors ...

Even after surgery and chemotherapy, some cancers, like pancreatic and colorectal, maintain a foothold in the body and ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...